FindTrial
Sign In

Xuebijing Injection

DRUG4 trials

Sponsors

Southeast University, China, Nanjing Medical University, The First Hospital of Hebei Medical University

Conditions

Acute Kidney InjuryAortic DissectionCardiovascular DiseaseCommunity Acquired PneumoniaCongenital Heart DiseaseCoronary Artery DiseaseCritical IllnessSepsis

Phase 4

The Efficacy of Xuebijing Injection on Sepsis
CompletedNCT03238742
Southeast University, ChinaSepsis
Start: 2017-10-20End: 2020-01-08Updated: 2021-01-05

Unknown Phase

Pharmacokinetics of XueBiJing in Patients With Sepsis
CompletedNCT03475732
Southeast University, ChinaCommunity Acquired Pneumonia, Sepsis, Septic Shock
Start: 2018-03-18End: 2019-12-31Updated: 2021-01-05
Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV
NCT04993794
Nanjing Medical UniversityAortic Dissection, Cardiovascular Disease, Congenital Heart Disease +3
Start: 2021-01-01End: 2022-12-31Target: 200Updated: 2021-08-10
Effect of Xuebijing in Alleviating Acute Kidney Injury After High-voltage Electrical Burns
CompletedNCT07026227
The First Hospital of Hebei Medical UniversityAcute Kidney Injury
Start: 2023-02-20End: 2023-11-30Updated: 2025-06-18

Related Papers

Xuebijing alleviates high-voltage electrical burn-induced acute kidney injury by inhibiting neutrophils and inflammation
Scientific Reports2025-08-191 citations
Treatment effects of Xuebijing injection in patients with sepsis by clinical phenotype: a post hoc analysis of the EXIT-SEP trial.
2025-07-09
Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis
JAMA Internal Medicine2023-05-0189 citations
Efficacy of Xuebijing Injection for Sepsis (EXIT-SEP): protocol for a randomised controlled trial
BMJ Open2019-08-0112 citations